跳到主要內容

臺灣博碩士論文加值系統

(100.28.2.72) 您好!臺灣時間:2024/06/16 06:36
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:陳冠文
研究生(外文):Kuan-Wen Chen
論文名稱:探討B型肝炎帶原者週邊血液PPARs基因表現與代謝因子、肝臟異常的關係
論文名稱(外文):Peripheral Blood PPARs Gene Expression, Metabolic Factors, and Liver Abnormalities in Chronic Hepatitis B
指導教授:于明暉于明暉引用關係
指導教授(外文):Ming-Whei Yu
口試委員:楊雅倩莊雅惠王姿乃林志陵
口試委員(外文):Tsu-Nai Wang
口試日期:2014-07-16
學位類別:碩士
校院名稱:國立臺灣大學
系所名稱:流行病學與預防醫學研究所
學門:醫藥衛生學門
學類:公共衛生學類
論文種類:學術論文
論文出版年:2014
畢業學年度:102
語文別:中文
論文頁數:38
中文關鍵詞:B型肝炎過氧化體增生活化受體PPARs代謝因子
外文關鍵詞:hepatitis BPPARsmetabolic factors
相關次數:
  • 被引用被引用:0
  • 點閱點閱:198
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
背景:研究顯示過氧化體增生活化受體(peroxisome proliferator-activated receptors, PPARs)的基因表現在調控脂質、血糖代謝與發炎反應扮演重要的角色。近期研究證實使用PPARs配體能有效治療非酒精性脂肪肝。
本研究目的為描述肝臟相關疾病的高危險群B型肝炎帶原者其週邊血液單核細胞之PPARs基因表現、代謝因子與肝臟異常的關聯性。

材料與方法:從1989年至1992年間招募的公務員世代中,選取共372位男性B型肝炎帶原者為研究對象。研究個案之糖尿病、BMI與血中轉氨&;#37238;於1989年進入研究時、追蹤期間和測量基因表現時量測;腰臀比與肝臟超音檢查則於追蹤期間與測量基因表現時被測定。本研究利用定量反轉錄聚合&;#37238;鏈反應分析PPARs於PBMCs的表現,並且以各個PPARs基因表現的中位數為切點將研究個案分為基因表現高和低兩組。最後用邏輯式迴歸分析PPARs基因表現、代謝因子和肝臟異常之間的關係。

研究結果:PPARα、PPARβ與PPARγ基因表現低與過重(BMI≧25 kg/m2)、腰臀比≧0.9和糖尿病等代謝因子呈顯著相關。此外,PPARα、PPARβ基因表現低皆和經肝臟超音波確診的肝硬化達顯著相關。經過年齡、抽菸、飲酒習慣、糖尿病與肝生化指標校正後,PPARα、PPARβ基因表現低其肝硬化的風險各為2.995 (95% CI:1.133-7.917)和2.730 (95% CI:1.010-7.379)。

結論:在B型肝炎帶原者中,週邊血液PPARs的基因表現量低為糖尿病的表徵,其相關條件可能與後期的肝臟疾病肝硬化有關。


Background: Studies have shown that peroxisome proliferator-activated receptors (PPARs) gene expression plays a critical role in lipid regulation, glucose metabolism and inflammation. The use of PPARs ligands was recently proved to be effective for treating non-alcoholic fatty liver disease. The aim of this study was to delineate the association between PPARs gene expression in peripheral blood mononuclear cells (PBMCs), metabolic factors and a spectrum of liver abnormalities among men with hepatitis B, who are at an extremely high risk of liver-related mortality.
Materials and Methods: The study subjects included a total of 372 male hepatitis B carriers, belonging to a cohort study of civil servants recruited in 1989-1992. History of diabetes mellitus (DM), body mass index (BMI) and blood transaminase were measured at study subjects’ enrollment into the cohort since 1989 and at follow-up and measurement of gene expression, while waist-to-hip ratio and ultrasonographic liver abnormalities were determined at follow-up and measurement of gene expression. We determined expression levels of PPARs in PBMCs by quantitative reverse transcription polymerase chain reaction. The median of each PPAR expression level was used as the cutoff point to categorize the subjects into “high” and “low” expression groups. Logistic regression was used to analyze the relationship between PPARs gene expression, metabolic factors, and liver abnormalities.
Results: Low PPARs gene expression were significantly associated with metabolic factors including overweight (BMI≧25 kg/m2), waist-hip ratio≧0.9 and prior DM. Furthermore, low expression of PPARα and PPARβ were significantly associated with liver cirrhosis detected by abdominal ultrasonography. After adjustment for age, cigarette smoking, alcohol consumption, DM, liver biochemical values, the odds ratio of liver cirrhosis was 2.995 (95% CI: 1.133-7.917) for low PPARα expression and 2.730 (95% CI: 1.010-7.379) for low PPARβ expression.
Conclusion: Low peripheral expression of PPARs that characterize DM and related conditions might be associated with advanced liver disease such as liver cirrhosis in hepatitis B carriers.


致謝 i
中文摘要 ii
ABSTRACT iii
CONTENTS v
研究背景 1
非酒精性脂肪肝 (Non-alcoholic fatty liver disease, NAFLD)1
過氧化體增生活化受體Peroxisome proliferator-activated receptors (PPARs) 3
週邊血液單核細胞( peripheral blood mononuclear cells, PBMCs)之基因表現 5
研究動機 5
材料與方法 7
研究個案與研究設計 7
週邊血液單核細胞(Peripheral Blood Mononuclear cells; PBMCs)的RNA萃取 7
反轉錄聚合鏈鎖反應 (Reverse transcription polymerase chain reaction;RT-PCR) 8
即時定量聚合鏈鎖反應 (Real-time quantitative polymerase chain reaction;Real-time qPCR)8
統計分析 9
結果 10
基本人口學、代謝因子與肝臟生化指標特徵 10
測量基因表現時肝臟異常與代謝因子異常之相關 10
測量基因表現時肝臟異常與進入研究世代時代謝因子、肝臟異常之相關 10
測量基因表現時代謝因子異常與進入研究世代時代謝因子、肝臟異常之相關 11
測量基因表現時肝臟異常與追蹤期間肝臟異常之相關 11
測量基因表現時代謝因子異常與追蹤期間肝臟異常之相關 11
PPARs基因表現與測量基因表現時肝臟異常之相關 12
PPARs基因表現與測量基因表現時代謝因子異常之相關 12
PPARs基因表現與測量基因表現時糖尿病、肝硬化之相關 12
討論 14
參考文獻 17


[1].Cheng, H.Y., et al. Nonalcoholic Fatty Liver Disease: Prevalence, Influence on Age and Sex, and Relationship with Metabolic Syndrome and Insulin Resistance. International Journal of Gerontology 2013; 7(4): p. 194-198.
[2].Marra, F., et al. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends in Molecular Medicine 2008; 14(2): 72-81.
[3].Vernon, G., A. Baranova, and Z.M. Younossi. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary Pharmacology &; Therapeutics 2011; 34(3): p. 274-285.
[4].Collantes, et al. Nonalcoholic fatty liver disease and the the epidemic of obesity epidemic of obesity. Cleveland and Clinic Journal of Medicine 2009; 71: 657-664.
[5].Chitturi S, Farrell GC, George J. Non-alcoholic steatohepattis in the Asia-Paci&;#64257;c region: future shock? J Gastroenterol Hepatol 2004; 19:368–374.
[6].Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998; 114:842–845.
[7].Souza MR., et al. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol 2012; 49(1):89-96.
[8].Birkenfeld, A.L. and G.I. Shulman. Nonalcoholic Fatty Liver Disease, Hepatic Insulin Resistance, and Type 2 Diabetes. Hepatology 2014; 59(2): p. 713-723.
[9].Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116:1413–1419.
[10].Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11:74–80
[11].Chalasani, N., et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55(6): p. 2005-2023.
[12].Baba, C.S., et al. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. Journal of Gastroenterology and Hepatology 2006; 21(1): p. 191-198.
[13].Lazo, M., et al., Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes. Diabetes Care 2010; 33(10): p. 2156-2163.
[14].Lisa B., et al. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Therapeutic Advances in Gastroenterology 2011; 4(4) ; 249-263.
[15].Loomba, R., et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Alimentary Pharmacology &; Therapeutics 2009; 29(2): p. 172-182.
[16].Marchesini G,Brizi M, Bianchi G, et al. Metformin non-alcoholic steatohepatitis. Lancet. 2001; 358:893-894.
[17].Tailleux, A., K. Wouters, et al. Roles of PPARs in NAFLD: Potential therapeutic targets. Biochimica Et Biophysica Acta-Molecular and Cell Biology of Lipids 2012; 1821(5): p. 809-818.
[18].Promrat, K., et al. A pilot study of ploglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39(1): p. 188-196.
[19].Renata Belfort., et al. A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis. N Engl J Med 2006; 355:2297-307.
[20].Neuschwander-Tetri, B.A., et al., Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38(4): p. 1008-1017.
[21].Ratziu, V., et al., Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology 2008; 135(1): p. 100-110.
[22].Ratziu, V., et al., Long-Term Efficacy of Rosiglitazone in Nonalcoholic Steatohepatitis: Results of the Fatty Liver Improvement by Rosiglitazone Therapy (FLIRT 2) Extension Trial. Hepatology 2010; 51(2): p. 445-453.
[23].Omer, Z., et al., Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. European Journal of Gastroenterology &; Hepatology 2010; 22(1): p. 18-23.
[24].Kallwitz, E.R.,et al. Role of peiroxisome proliferators-activated receptors in the pathogenesis and treatment of nonaloholic fatty liver disease. World Journal of Gastroenterology 2008; 14(1): p. 22-28.
[25].Ip, E., et al., Central role of PPAR alpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003; 38(1): p. 123-132.
[26].E. Ip, G. Farrell, P. Hall, G. Robertson, I. Leclercq. Administration of the potent
PPARalpha agonist, Wy-14,643, reverses nutritional &;#64257;brosis and steatohepatitis in mice. Hepatology 2004; 39:1286–1296.
[27].Yeon, J.E., et al. Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2004; 19(7): p. 799-804.
[28].Nakamuta, M., et al., Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation. Transplantation 2005; 80(5): p. 608-612.
[29].Fernandez-Miranda, C., et al. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Digestive and Liver Disease 2008; 40(3): p. 200-205.
[30].Promrat, K., et al. Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic Steatohepatitis. Hepatology 2010; 51(1): p. 121-129.
[31].Tatsuya Nagasawa., et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPAR δ agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. European Journal of Pharmacology. 2006; 536: 182 – 191.
[32].E. Moran-Salvador., et al. Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage- speci&;#64257;c conditional knockouts. FASEB J 2011; 25: 2538–2550.
[33].O. Gavrilova., et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem 2003; 278: 34268–34276.
[34].S. Yu., et al. Adipocyte-speci&;#64257;c gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J. Biol. Chem 2003; 278: 498–505.
[35].Riserus, U., et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatly acid oxidation in moderately obese men. Diabetes 20085; 7(2): p. 332-339.
[36].Etsuko Hashimoto and Geoffrey C Farrel. Will non-invasive makers replace liver biopsy for diagoning and staging fibrosis in non-alocoholic seatohepatitis?. Journal of Gastroentero and Hepatology 2009; 24: 564-568.
[37].Liew, C. C., et al. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. Journal of Laboratory and Clinical Medicine 2006; 147(3): 126-132.
[38].Connolly, P.H., et al. Effects of exercise on gene expression in human peripheral blood mononuclear cells. Journal of Applied Physiology 2004; 97(4): p. 1461-1469.
[39].Oliver, P., et al. Peripheral blood mononuclear cells: a potential source of homeostatic imbalance markers associated with obesity development. Pflugers Archiv-European Journal of Physiology 2013; 465(4): 459-468.
[40].Manoel-Caetano, F. S., et al. Gene expression profiles displayed by peripheral blood mononuclear cells from patients with type 2 diabetes mellitus focusing on biological processes implicated on the pathogenesis of the disease. Gene 2012; 511(2): 151-160.
[41].Takamura, T., et al. Gene expression profiles in peripheral blood mononuclear cells reflect the pathophysiology of type 2 diabetes. Biochemical and Biophysical Research Communications 2007; 361(2): 379-384.
[42].Shi, M., et al. A blood-based three-gene signature for the non-invasive detection of early human hepatocellular carcinoma. European Journal of Cancer 2004; 50(5): 928-936.
[43].de Mello, V.D.F., et al. Gene expression of peripheral blood mononuclear cells as a tool in dietary intervention studies: What do we know so far? Molecular Nutrition &; Food Research 2012; 56(7): p. 1160-1172.
[44].Garcia-Fuentes, E., et al. PPAR gamma Expression After a High-fat Meal Is Associated With Plasma Superoxide Dismutase Activity in Morbidly Obese Persons. Obesity 2010; l18(5): p. 952-958.
[45].Macias-Gonzalez, M., et al. PPAR gamma mRNA expression is reduced in peripheral blood mononuclear cells after fat overload in patients with metabolic syndrome. Journal of Nutrition 2008; 138(5): p. 903-907.
[46].Machado, M.V., et al. Hepatic steatosis in hepatitis B virus infected patients: Meta-analysis of risk factors and comparison with hepatitis C infected patients. Journal of Gastroenterology and Hepatology 2011; 26(9): p. 1361-1367.
[47].Chen, C.H., et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: Metabolic significance of nonalcoholic fatty liver disease in nonobese adults. Journal of Clinical Gastroenterology 2006. 40(8): p. 745-752.
[48].Hsu, C.S. and J.H. Kao. Non-alcoholic fatty liver disease: An emerging liver disease in Taiwan. Journal of the Formosan Medical Association 2012; 111(10): p. 527-535.
[49].Lin, Y.C., et al. Risk factors and predictors of non-alcoholic fatty liver disease in Taiwan. Annals of Hepatology 2011; 10(2): p. 125-132.
[50].Liu, C.J., et al. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. Journal of Gastroenterology and Hepatology 2012; 27(10): p. 1555-1560.
[51].Yu, M. W., et al. Body-Mass Index and Progression of Hepatitis B: A Population-Based Cohort Study in Men. Journal of Clinical Oncology 2008; 26(34): 5576-5582.
[52].Dubuquoy,L.,et al. Peroxisome Proliferator-Activated Receptors in HBV-Related Infection. Ppar Research 2009; p. 6.
[53].Bas A, Forsberg G, Hammarstrom S, Hammarstrom ML. Utility of the Housek- eeping Genes 18S rRNA, β-Actin and Glyceraldehyde-3-Phosphate-Dehydroge- nase for Normalization in Real-Time Quantitative Reverse Transcriptase-Poly- mmerase Chain Reaction Analysis of Gene Expression in Human TLymphocytes. Scandinavian Journal of Immunology 2004; 59(6):566-573.
[54].Livak, K.J. and T.D. Schmittgen. Analysis of relative gene expression data usi- ng real-time quantitative PCR and the 2(-Delta Delta C(T)). Methods 2001; 25:402-408.
[55].Wang, Y.-X. PPARs: diverse regulators in energy metabolism and metabolic diseases. Cell Research 2010; 20(2): 124-137.
[56].Stranges, S., et al. Body fat distribution, relative weight, and liver enzyme levels: A population-based study. Hepatology 2004; 39(3): 754-763.
[57].Service d’hepatologie, et al. HBV-carriers: When is monitoring and surveillance suf&;#64257;cient? (point of view). Clinics and Research in Hepatology and Gastroent- erology 2011; 35: 813—818.
[58].Lars la Cour Poulsen, et al. PPARs: Fatty acid sensors controlling metabolism. Seminars in Cell &; Developmental Biology 2012; 23: 631–639.
[59].Joel P. Berger, et al. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005 ;26(5):244-51.
[60].Duval C, Fruchart JC, Staels B. PPAR alpha, fibrates, lipid metabolism and inflammation. Arch Mal Coeur Vaiss 2004; 97:665–672.
[61].Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J ClinInvest 1999; 103:1489–1498.
[62].Chawla A, Lee CH, Barak Y, et al. PPARdelta is a very low-density lipoprotein sensor in macrophages. Proc Natl Acad Sci U S A 2003;100:1268–1273.
[63].Lee CH, Kang K, Mehl IR, et al. Peroxisome proliferator-activated receptor delta promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage.Proc Natl Acad Sci U S A 2006; 103:2434–2439.
[64]. Lee CH, Olson P, Hevener A, et al. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci U S A 2006; 103:3444–3449.
[65].Robert K. Semple, et al. PPARγ and human metabolic disease. &;#8194;J. Clin. Invest 2006; 116:581–589.
[66].Waltr Wahli, et al. PPARs at crossroads of lipid signaling and inflammation. Trends in Endocrinology and Metabolism 2012; 23:351-363.
[67].Rinke Stienstra, et al. PPARs, Obesity, and In&;#64258;ammation. PPAR Research 2007; 2007:95974.
[68].Yuan Tian, et al. Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. Seminars in Cancer biology 2003; 23:471-482.
[69].Gyorgy Baffy, et al. Hepatocellular carcinoma in non-alcoholic fatty liver disease : An emerging menace. Journal of hepatology 2012; 56: 1384–1391
[70].Nakanishi N, Suzuki K, Tatara K. Serum gamma-glutamyltran- sferase and risk of metabolic syndrome and type 2 diabetes in middle-aged japanese men. Diabetes Care 2004; 27(6):1427–32.
[71].Xiaowen Liu, et al. Circulating alanine transaminase (ALT) andγ-glutamyl transferase (GGT), but not fetuin-A, are associatd with metabolic risk factors, at baseline and at two-year follow-up: The prospective Cyprus Metabolism Study. Metabolism Clinical and Experimental 2010; 63 (2014) 773-782.


QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top